Home >
Access the latest news, business developments, company updates, industry trends, events and more.
SpringWorks Therapeutics reports that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis) trial evaluating nirogacestat, an oral, selective, small molecule gamma-secretase...
Azitra has announced the appointment of two distinguished scientists to expand the technical team and lead the expansion of its development programs. Travis Whitfill, co-founder, will...
Bioarray Genetics has been selected to present at the 2019 International Cancer Cluster Showcase as part of its North American and European cutting-edge oncology innovations group....
Achillion Pharmaceuticals has reported positive interim data from a Phase 2 paroxysmal nocturnal hemoglobinuria (PNH) trial assessing the safety and effectiveness of its oral small...
IsoPlexis has raised $25 million in Series C funding. The round was led by Northpond Ventures and included new strategic investment along with current investors...
While cases of syphilis in Europe were first recorded over 500 years ago, no vaccine candidates have ever advanced to human clinical trials. A new...
NextCure announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share....
Trevi Therapeutics has gone public, selling 5.5 million shares at $10 a share and raising $55 million. The company, which is developing a drug for...
SpringWorks Therapeutics reports that the first patient has been dosed in a Phase 1b study to evaluate the combination of SpringWorks Therapeutics’ investigational MEK inhibitor,...
Yale-New Haven Hospital has unveiled plans to build up its St. Raphael campus with a 505,000-square foot, $838 million neuroscience center for research and treatment...